Perrigo’s Loss Is Lupin’s Gain
Somerset Site Gets 13 Observations
Having gained from Perrigo’s withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by Q4 as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility are a dampener
